$goss

$GOSS is seeing a surge in social engagement, driven by anticipation for its Phase [--] readout and potential market disruption. However, market sentiment is mixed, with options data indicating significant risk.

About $goss

$GOSS refers to a decentralized digital currency and its associated blockchain technology.

Engagements: [------] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-----]
[--] Week: [------] +3,402,800%
[--] Month: [-------] -48%
[--] Months: [---------] +128%
[--] Year: [---------] +196%
1-Year High: [-------] on 2025-12-24
1-Year Low: [--] on 2025-05-10

Engagements by network (24h): X: [------] Reddit: [--]

Mentions: [--] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [-----] on 2025-07-10
1-Year Low: [--] on 2025-04-27

Mentions by network (24h): X: [--] Reddit: [--]

Creators: [--] (24h)

Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $goss in the last [--] hours which is down 15% from [--] in the previous [--] hours Daily Average: [--]
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-27

The most influential creators that mention $goss in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	[--]	[------]	[--]	[------]
@avidresearch	[--]	[------]	[--]	[-----]
@RiskInhibitor	[--]	[--]	[--]	[-----]
@semodough	[--]	[------]	[--]	[---]
@FWCWeather	[--]	[---]	[--]	[---]
@trentkelp	[--]	[-----]	[--]	[---]
@BOSSTRADING0	[--]	[-----]	[--]	[---]
@Biopharma_Watch	[--]	[-----]	[--]	[---]
@Buffalo51766917	[--]	[---]	[--]	[---]
@DanVibes10	[--]	[-----]	[--]	[---]

View More

Sentiment: 92%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 92%
Daily Average: 85%
[--] Month: 91% +39%
[--] Months: 91% -9%
[--] Year: 91% +16%
1-Year High: 100% on 2025-02-18
1-Year Low: 14% on 2025-11-11

Most Supportive Themes:

• Positive Phase [--] Readout Anticipation: (40%) Multiple posts express optimism about an upcoming Phase [--] readout for $GOSS, with analysts from Barclays, HC Wainwright, and Piper Sandler providing supportive price targets.
• Potential for Disease Modification and Market Share: (30%) Discussions highlight $GOSS's potential as a second disease-modifying drug, with analysis on how it could capture market share by catering to specific patient groups or offering convenience.
• Biotech Catalyst Watchlist Inclusion: (20%) $GOSS is listed among key biotech stocks with upcoming Phase [--] and Phase [--] readouts in Q1 2026, indicating significant industry attention.

Most Critical Themes:

• Options Market Pricing in Failure Risk: (10%) Options data suggests a 70% probability of failure for the Phase [--] readout, with concerns about patient enrollment and statistical significance in previous phases.

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing